Daniel Spiegelman Buys Shares of VTVT
Daniel Spiegelman acquired 6,000 shares of VTVT on June 26, 2026.
Key Points
- Daniel Spiegelman purchased 6,000 shares of VTVT at $35.08 per share on June 26, 2026, totaling $210,480.
- VTVT shares traded near $36.27 on Tuesday, with significant insider activity reported.
- Analysts from Evercore ISI Group, BTIG, and others maintain a 'buy' rating on VTVT with price targets ranging from $40 to $67.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 26, 2026, Daniel Spiegelman bought 6,000 shares of VTVT at an average price of $35.08 per share. This purchase amounted to a total value of $210,480. The transaction was not planned under a Rule 10b5-1 trading plan.
Insider Buying and Selling at vTv Therapeutics Inc.
On the same day, several other insiders, including Srinivas Akkaraju, Anne Phillips, and Fahed Al-Marzooqi, each acquired 6,000 shares at the same price. Paul Sekhri, the President, CEO, and Executive Chairperson, made an earlier purchase of 140,000 shares at $36.92 on February 17, 2026.
Other Institutional Activity in VTVT
Samsara Biocapital, LLC maintained its position in VTVT with 298,496 shares valued at approximately $11.84 million. FMR LLC reduced its holdings by 8,465 shares, now holding 260,391 shares worth about $10.33 million, marking a 3.1% decrease. Millennium Management LLC opened a new position with 206,288 shares valued at $8.18 million. Trails Edge Capital Partners, LP cut its stake by 91,422 shares, now holding 139,578 shares valued at $5.54 million, reflecting a 39.6% decrease.
Analysts Set New Price Targets
On March 12, 2026, Evercore ISI Group initiated coverage on VTVT with a 'buy' rating and a $44 price target. BTIG maintained its 'buy' rating with a $49 target on January 27, 2026. Analysts from Roth Capital and TD Cowen have also initiated 'buy' ratings with targets of $58 and $67, respectively. The consensus among analysts is a 'buy', with an average target price reflecting optimism for the stock's future performance.
Bottom Line
This recent insider buying activity at VTVT signals confidence from its leaders, including Daniel Spiegelman. Investors often track such moves for insights into company prospects. The analyst community remains bullish on VTVT, with several firms maintaining 'buy' ratings and setting ambitious price targets. However, it's important to remember that insider transactions and analyst ratings are just parts of the broader investment picture.
Get vTv Therapeutics Inc. alerts
New 13F filings, insider trades, and analyst moves on $VTVT, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.